Heavyweight, French eunitel pharmaceutical launched the acquisition of Nanjing r
On August 25, 2020, Paris, France and Jiangsu, China:
Through the acquisition of best, yountel will strengthen its development in China, the world's second largest pharmaceutical market, and complement its industrial map outside Europe, the United States and Brazil. "We are very pleased to welcome this new company into the yountel group, which will enable us to carry out processing operations in China," explained Eric Goupil, chief executive of yountel. This is in line with our strategy of producing close to the end market. "
Photos of some on-site contract signing
Through the acquisition, yountel will provide services to local and multinational pharmaceutical companies developing ophthalmology and respiratory markets in China, producing sterile, preservative free single dose formulations in China.
<p style="margin: 0px 10px; padding: 0px; font-size: 17px; line-height: 1.75em; color: rgb(51, 51, 51); max-width: 100%; clear: both; min-height: 1em; font-family: -apple-system-font, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" letter-spacing:="" 0.544px;="" text-align:="" justify;="" box-sizing:="" border-box="" !important;="" overflow-wrap:="" break-word="" !important;"="">
Nanjing ruinian best Pharmaceutical Co., Ltd. is a pharmaceutical enterprise located in Nanjing, Jiangsu Province, focusing on the production of solid and liquid preparations, with a turnover of 10 million euro and 130 employees. It belongs to the important assets of Wuxi Jinyuan Industry Investment Development Group Co., Ltd., which is the government investment platform of Wuxi Binhu District.
Eunitel Pharmaceutical Group was founded in 1993 by acquiring a 17 employee factory in Amiens, France. Today, as a global leader in pharmaceutical manufacturing, we produce sterile single dose formulations and strip pouch formulations including eye drops, nasal care solutions and aerosol inhalation products for original research and generic drug customers.
The group has six production bases and one innovation and Research Center in France, the United States and Brazil, with a turnover of 319 million euros in 2019. At present, the group has more than 1500 employees, and continues to consolidate its global leadership in the field of aseptic preparation production.
In March 2017, yountel group completed the fourth financing merger and acquisition by Ardian, keensight capital and parquest capital from the original shareholders equistone partners Europe and management.
